Propofol in chemotherapy-associated nausea and vomiting.
Propofol appears to possess antiemetic actions. Limited reports have shown benefit with its use as adjuvant therapy with highly emetogenic chemotherapy regimens and as monotherapy with moderately emetogenic chemotherapy. Adverse effects have been minimal. It should be noted that to date no Phase I dose ranging studies have been described; therefore, optimal dose and duration remain unknown. Results from well-designed, controlled clinical trials in large numbers of patients are needed to define the appropriate role of propofol in antiemetic therapy. Currently, propofol must be reserved for use in clinical trials or as adjuvant therapy for patients refractory to standard 5-HT3 antagonist and corticosteroid antiemetic prophylaxis.
Phelps
K C
KC
Department of Pharmacy, North Carolina Baptist Hospital, Winston-Salem, USA.
Restino
M S
MS
D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D015742:Propofol / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
D000932:Antiemetics; D000970:Antineoplastic Agents; D006993:Hypnotics and Sedatives; D015742:Propofol